Valuation: Grace Therapeutics, Inc.

Market Cap 6.7Cr 4.82Cr 4.17Cr 3.95Cr 3.57Cr 462.06Cr 6.75Cr 47Cr 18Cr 234.29Cr 18Cr 18Cr 747.18Cr P/E 2027 *
-1.91x
P/E 2028 * -4.98x
Enterprise Value 6.7Cr 4.82Cr 4.17Cr 3.95Cr 3.57Cr 462.06Cr 6.75Cr 47Cr 18Cr 234.29Cr 18Cr 18Cr 747.18Cr EV / Sales 2027 *
-
EV / Sales 2028 * 9.8x
Free-Float
81.32%
Yield 2027 *
-
Yield 2028 * -
1 day-3.06%
1 week+4.48%
Current month+3.99%
1 month+2.55%
3 months+0.23%
6 months-49.89%
Current year-35.98%
1 week 2.07
Extreme 2.07
2.46
1 month 2.04
Extreme 2.04
2.46
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
14.28
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 55 05/01/2024
Chief Tech/Sci/R&D Officer 65 08/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 04/04/2023
Director/Board Member 59 10/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26
Opaleye Management, Inc.
BuyCompany 5,836 0.0277%
09/09/26 Buy

Chief Executive Officer

1,00,000 0.4754%
28/08/26 Free

Executive/Senior Manager

35,760 0.1700%
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%+4.48%-27.85%+10.20% 4.82Cr
-1.38%+2.23%+48.54%+100.96% 7.02TCr
-1.04%-0.81%+34.61%+75.16% 6.26TCr
-4.78%-4.42%-16.61%+348.59% 2.74TCr
+0.16%+1.53%+34.92%+17.47% 2.57TCr
-1.72%-1.23%-0.44%-13.81% 2.48TCr
+1.61%-0.69%+20.85%-19.42% 1.95TCr
+1.26%-9.06%+165.21%+308.08% 1.55TCr
-3.91%-5.71%-8.71%+521.92% 1.47TCr
-5.89%+0.35%-8.45%+827.27% 1.47TCr
Average -1.87%-0.29%+24.21%+217.64% 2.75TCr
Weighted average by Cap. -1.55%-0.64%+31.71%+165.88%

Financials

2027 *2028 *
Net sales - 68.41L 49.15L 42.58L 40.26L 36.45L 47Cr 68.92L 4.8Cr 1.85Cr 24Cr 1.85Cr 1.81Cr 76Cr
Net income -3.47Cr -2.5Cr -2.16Cr -2.04Cr -1.85Cr -239.37Cr -3.5Cr -24Cr -9.38Cr -121.37Cr -9.37Cr -9.17Cr -387.08Cr -1.69Cr -1.22Cr -1.05Cr -99.56L -90.14L -116.6Cr -1.7Cr -12Cr -4.57Cr -59Cr -4.57Cr -4.46Cr -188.55Cr
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
15/26/15 $2.215 -3.28% 47,135
14/26/14 $2.290 +3.15% 48,338
11/26/11 $2.220 -1.77% 7,16,523
10/26/10 $2.260 +5.61% 3,97,539
09/26/09 $2.140 +0.94% 2,24,665
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.187CAD
Average target price
8.342CAD
Spread / Average Target
+161.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!